Abstract:Background: Children with neurodevelopmental disorders have a high risk of sleep disturbances, with insomnia being the most common sleep disorder (ie, chronic and frequent difficulties with going and staying asleep). Insomnia adversely affects the well-being of these children and their caregivers. Pediatric sleep experts recommend behavioral interventions as the first-line treatment option for children. Better Nights, Better Days for Children with Neurodevelopmental Disorders (BNBD-NDD) is a 5-session eHealth behavioral intervention delivered to parents to improve outcomes (eg, Pediatric Quality of Life Inventory [PedsQL]) for their children (ages 4-12 years) with insomnia and who have a diagnosis of mild to moderate attention-deficit/hyperactivity disorder, autism spectrum disorder, cerebral palsy, or fetal alcohol spectrum disorder. If cost-effective, BNBD-NDD can be a scalable intervention that provides value to an underserved population. Objective: This protocol outlines an economic evaluation conducted alongside the BNBD-NDD randomized controlled trial (RCT) that aims to assess its costs, efficacy, and cost-effectiveness compared to usual care. Methods: The BNBD-NDD RCT evaluates the impacts of the intervention on children's sleep and quality of life, as well as parents' daytime functioning and psychosocial health. Parent participants were randomized to the BNBD-NDD treatment or to usual care. The economic evaluation assesses outcomes at baseline and 8 months later, which include the PedsQL as the primary measure. Quality of life outcomes facilitate the comparison of competing interventions across different populations and medical conditions. Cost items include the BNBD-NDD intervention and parent-reported usage of private and publicly funded resources for their children's insomnia. The economic evaluation involves a reference case cost-effectiveness analysis to examine the incremental cost of BNBD-NDD per units gained in the PedsQL from the family payer perspective and a cost-consequence analysis from a societal perspective. These analyses will be conducted over an 8-month time horizon. Results: Research funding was obtained from the Kids Brain Health Network in 2015. Ethics were approved by the IWK Health Research Ethics Board and the University of Calgary Conjoint Health Research Ethics Board in January 2019 and June 2022, respectively. The BNBD-NDD RCT data collection commenced in June 2019 and ended in April 2022. The RCT data are currently being analyzed, and data relevant to the economic analysis will be analyzed concurrently. Conclusions: To our knowledge, this will be the first economic evaluation of an eHealth intervention for insomnia in children with neurodevelopmental disorders. This evaluation's findings can inform users and stakeholders regarding the costs and benefits of BNBD-NDD. Trial registration: ClinicalTrial.gov NCT02694003; https://clinicaltrials.gov/study/NCT02694003. International registered report identifier (irrid): DERR1-10.2196/46735.

0843 Improving Daytime Sleepiness in Children with Narcolepsy: A Quality Improvement Initiative

Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea

Protecting Sleep Hygiene in the PICU: A Quality Improvement Project

1061 Improving Access to Pediatric Sleep Service by Utilizing Unique Electronic Medical Record Based Informatic Tools

Circadian Rhythm of Daytime Sleepiness in Pediatric Narcolepsy: A Pilot Study

Quality improvement and practice-based research in sleep medicine using structured clinical documentation in the electronic medical record

An eHealth Program for Insomnia in Children With Neurodevelopmental Disorders (Better Nights, Better Days): Protocol for an Economic Evaluation of a Randomized Controlled Trial

0640 Magnitude of Improvement in Excessive Daytime Sleepiness with the Once-at-Bedtime Oxybate for Narcolepsy

1171 Hypersomnia Secondary to Long Covid

Narcolepsy Severity Scale-2 and Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and consequences in Narcolepsy type 2

A Quality Improvement Initiative for Detection of Attention-Deficit/Hyperactivity Disorder in an Urban, Academic Safety Net Hospital

1040 Improved Care in Neuromuscular Multidisciplinary Clinic with Sleep Medicine Incorporation

P055 Maintaining effectiveness and mitigating sleepiness: A tailored digital CBT-i approach.

Effectiveness of an intervention program on physical activity in children with narcolepsy type 1

0667 Narcolepsy & Idiopathic Hypersomnia Patient Journey, Clinical Features and Treatments in a Real-World US Population

Development and Validation of the Narcolepsy Severity Scale in School Aged Children.

0658 Validity and Reliability of the Pediatric Narcolepsy Patient-Reported Outcomes Scale (PN-PROS)

Screening for Quality of Life in a Neurology Tic Clinic Using Quality Improvement Methodology

0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 1

Increasing the use of anxiolysis and analgesia for paediatric procedures in a community emergency department network: a quality improvement initiative

The Impact of Symptom Severity on Health-Related Quality of Life in People with Narcolepsy Type 1